Key Takeaways
- A CMS proposed rule requiring Medicare and Medicaid to cover obesity drugs would cost the federal government $25bn over 10 years in Medicare and federal and state governments $15bn in Medicaid, according to the agency.
- The policy involves a ‘reinterpretation’ of the law informed by recent advances in obesity treatments.
- The incoming Trump Administration will decide whether to finalize the rule.
Medicare Part D and Medicaid coverage of anti-obesity medications would increase federal and state spending by $40bn over 10 years, the Centers for Medicare and Medicaid Services estimated in a...
The policy long sought by manufacturers and patient groups is part of the 2026 Policy and Technical Changes to the Medicare Advantage and Medicare Part D Programs proposed rule.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?